RESEARCH ARTICLE

Sympathoadrenal Activation and Endothelial Damage Are Inter Correlated and Predict Increased Mortality in Patients Resuscitated after Out-Of-Hospital Cardiac Arrest. A Post Hoc Sub-Study of Patients from the TTM-Trial

Pär I. Johansson1,2*, John Bro-Jeppesen3, Jesper Kjaergaard3, Michael Wanscher4, Christian Hassager3, Sisse R. Ostrowski1

1 Section for Transfusion Medicine Capital Region Blood Bank, Rigshospitalet, Copenhagen, Capital Region, Denmark, 2 Department of Surgery and Division of Acute Care Surgery, Centre for Translational Injury Research (CeTIR) at University of Texas Medical School at Houston, Houston, Texas, United States, 3 Department of Cardiology, Rigshospitalet, Copenhagen, Capital Region, Denmark, 4 Department of Cardiothoracic Anesthesiology The Heart Center, Rigshospitalet, Copenhagen, Capital Region, Denmark

* per.johansson@regionh.dk

Abstract

Objective

Sympathoadrenal activation and endothelial damage are hallmarks of acute critical illness. This study investigated their association and predictive value in patients resuscitated from out-of-hospital cardiac arrest (OHCA).

Methods

Post-hoc analysis of patients included at a single site in The Targeted Temperature Management at 33 degrees versus 36 degrees after Cardiac Arrest (TTM) trial. The main study reported similar outcomes with targeting 33 versus 36 degrees. TTM main study ClinicalTrials.gov: NCT01020916. One hundred sixty three patients resuscitated from OHCA were included at a single site ICU. Blood was sampled a median 135 min (Inter Quartile Range (IQR) 103-169) after OHCA. Plasma catecholamines (adrenaline, noradrenaline) and serum endothelial biomarkers (syndecan-1, thrombomodulin, sE-selectin, sVE-cadherin) were measured at admission (immediately after randomization). We had access to data on demography, medical history, characteristics of the OHCA, patients and 180-day outcome.

Results

Adrenaline and noradrenaline correlated positively with syndecan-1 and thrombomodulin i.e., biomarkers reflecting endothelial damage (both p<0.05). Overall 180-day mortality was 35%. By Cox analyses, plasma adrenaline, serum sE-selectin, reflecting endothelial cell activation, and thrombomodulin levels predicted mortality. However, thrombomodulin was the...
only biomarker independently associated with mortality after adjusting for gender, age, rhythm (shockable vs. non-shockable), OHCA to return of spontaneous circulation (ROSC) time, shock at admission and ST elevation myocardial infarction (30-day Hazards Ratio 1.71 (IQR 1.05-2.77), p=0.031 and 180-day Hazards Ratio 1.65 (IQR 1.03-2.65), p=0.037 for 2-fold higher thrombomodulin levels).

Conclusions
Circulating catecholamines and endothelial damage were intercorrelated and predicted increased mortality. Interventions aiming at protecting and/or restoring the endothelium may be beneficial in OHCA patients.

Introduction
Out-of-hospital cardiac arrest (OHCA) is a leading cause of death among adults in the developed world. Despite state-of-the-art treatment from the earliest prehospital phase to hospital discharge, less than 30% survive, and many with poor functional outcome [1, 2]. Although most patients die in the earliest phase due to absent return of spontaneous circulation (ROSC), patients admitted to the hospital and intensive care unit (ICU) still face high mortality rates or survive with significant disabilities [1, 2]. One reason for the poor in-hospital outcome is the development of Post-Cardiac Arrest Syndrome (PCAS), characterized by varying degrees of 1) anoxic brain injury, 2) arrest-related myocardial dysfunction, 3) systemic ischemia/reperfusion injury and 4) persistent precipitating pathology i.e., the cause of cardiac arrest [3, 4]. PCAS results from a pathophysiologic process driven by a whole-body ischemia/reperfusion response, which triggers immediate and excessive activation of the inflammatory and hemostatic systems, leading to a sepsis-like syndrome [5] with ultimate development of (multiple) organ failure [3, 4]. Thus, similar to sepsis [6], OHCA patients present with excessive endothelial damage from the earliest phase of resuscitation [7–9].

Microcirculatory failure is a hallmark of acute critical illness: It is caused by numerous injurious hits on the vascular system, including the endothelium, and it is a driver of organ failure and thereby closely linked to outcome [6]. One of the hits encountered by the vascular system and endothelium in acute critical illness, including cardiac arrest, is a toxic high level of catecholamines [10–13], either endogenously released following excessive sympathoadrenal activation [14, 15] and/or exogenously administered as vasopressor/inotropic therapy [16, 17]. We have previously demonstrated associations between- and negative predictive values of high circulating catecholamines and endothelial damage in trauma [18, 19], sepsis [20] and ST segment elevation myocardial infarction (STEMI) [21] patients. However, no studies have previously investigated the association between circulating catecholamines, endothelial damage and outcome in cardiac arrest patients.

The objective of the present study was to investigate the association between sympathoadrenal activation, endothelial damage and outcome in OHCA patients, hypothesizing that excessive sympathoadrenal activation and endothelial damage would be associated and linked to poor outcome. We had access to previously collected plasma samples from OHCA patients included at a single site (Copenhagen, Denmark) in The Targeted Temperature Management at 33 degrees C versus 36 degrees C after Cardiac Arrest (TTM) trial [22]. The main TTM study reported similar outcomes with targeting 33 versus 36 degrees [22].
**Materials and Methods**

**Trial protocol and patients**

The present study represents a post hoc sub-study of patients from TTM trial (ClinicalTrials.gov number NCT01020916), a randomized clinical trial recruiting patients in 36 intensive care units (ICUs) in Europe and Australia [22]. The present sub-study was planned after conduct of the TTM-trial and after disclosure of the database from the TTM-trial.

The TTM protocol was approved by the ethics committees in each participating country and institution (in Denmark by the regional ethical committee (H-1-2010-059) and the Danish Data Protection Agency) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from a legal surrogate and from all patients who regained mental capacity [22]. Participant consent was documented as a signed consent form that was kept according to Danish Legislation. The procedure for obtaining written informed consent was approved by the ethics committee. The TTM inclusion criteria were patients ≥18 years of age who were unconscious (Glasgow Coma Scale (GCS) < 8) on admission to the hospital after OHCA of presumed cardiac cause, irrespective of the initial rhythm. Eligible patients had more than 20 consecutive minutes of spontaneous circulation after resuscitation. The main exclusion criteria were an interval from the ROSC to screening of more than 240 minutes, unwitnessed arrest with asystole as the initial rhythm, suspected or known acute intracranial hemorrhage or stroke and a body temperature of less than 30°C [22].

Eligible patients for the present study were patients included at Rigshospitalet, Copenhagen University Hospital, Denmark (in total n = 171). Furthermore, to be included, an adequate volume of stored plasma and serum should be available from the pre-intervention admission blood sample to allow for investigation of the planned biomarkers (fulfilled in n = 163 as eight patients had too little sample volume to perform the planned biomarker analyses). The present study is based on these 163 patients.

We had access to the following data as part of the TTM trial protocol: Demography, medical history, characteristics of the cardiac arrest, patient characteristics at admission and outcome (mortality, Cerebral Performance Category (CPC) and modified Rankin scale (mRS); all surviving patients were followed until 180 days after the enrollment of the last patient) [22].

**Blood samples**

Blood was sampled from an arterial line within 5 minutes following inclusion and randomization in the study. The sample was divided for blood gas analysis (ABG, Radiometer ABL 725/735, Copenhagen, Denmark), routine biochemistry and research analyses (citrate, heparin and EDTA plasma, serum). All samples were centrifuged immediately at 4°C. Plasma and serum aliquots were stored at -80°C until thawed for analysis.

**Enzyme linked immunosorbent assay (ELISA) analyses**

Biomarkers of sympathoadrenal activation (adrenaline, noradrenaline) and endothelial glyco-calyx damage (syndecan-1) [23], endothelial cell activation (sE-selectin) [24, 25], endothelial cell injury (soluble thrombomodulin) [24–26] and endothelial junction disruption (sVE-cadherin) [27] were measured in uniplicate by commercially available immunoassays in EDTA plasma (catecholamines) and serum (endothelial biomarkers) according to the manufactures recommendations: Plasma (p)-adrenaline and p-noradrenaline (2-CAT ELISAFAST TRACK, Labor Diagnostica Nord GmbH & Co. KG, Nordhorn, Germany; lower limit of detection (LLD) 10 pg/ml (adrenaline) and 50 pg/ml (noradrenaline), respectively); syndecan-1 (Diaclone, Nordic Biosite, Copenhagen, Denmark; LLD 4.94 ng/ml); sE-selectin (R&D Systems...
Europe, Ltd., Abingdon, UK; LLD 0.009 ng/ml); thrombomodulin (Diaclone, Nordic Biosite, Copenhagen, Denmark; LLD 0.31 ng/ml) and sVE-cadherin (R&D Systems Europe, Ltd., Abingdon, UK; LLD 0.113 ng/ml). Values below LLD were recorded as the LLD value (n = 5 for adrenaline, n = 3 for noradrenaline, none for the remaining biomarkers).

**Statistics**

Statistical analysis was performed using SAS 9.1.3 SP4 (SAS Institute Inc., Cary, NC, US). Patients stratified according to shockable rhythm (yes vs. no, see Table 1 legend for definition) or high vs. low thrombomodulin level (high: >median vs. low: ≤median) were compared by Mann-Whitney U test or Chi-square/Fisher’s exact tests, as appropriate.

Simple correlations were investigated by Spearman’s correlations with results displayed as rho and p-values. To investigate the contribution of p-catecholamines, individual biomarkers of endothelial activation or damage, characteristics of the OHCA and demographic variables to the variation in levels of the endothelial biomarkers (syndecan-1, thrombomodulin, sE-selectin and sVE-cadherin), multivariate backwards linear regression analysis were performed including variables that were either found to correlate with or expected to influence the investigated biomarkers: Age, BMI, number of defibrillations, time from OHCA to ROSC, pH, p-adrenaline, p-noradrenaline, syndecan-1, sE-selectin, thrombomodulin, sVE-cadherin and ECG finding at admission (STEMI vs. other). Results are presented as regression coefficients (β) with 95% confidence intervals (CI), p-values and adjusted R².

The predictive value of admission p-catecholamines (dichotomized by the median: high vs. low) and biomarkers of endothelial activation and damage (log2 transformed) for 7-day, 30-day and 180-day mortality was investigated by univariate and multivariate Cox proportional-hazards models, the latter after adjusting for previously described [22] predictive variables: Age, gender, rhythm (shockable vs. non-shockable), time from OHCA to ROSC, shock at admission and admission ECG finding (STEMI vs. other). Results are presented as hazards ratio (HR) with 95% CI and p-values. Furthermore, the predictive value of high vs. low p-catecholamines and biomarker levels (dichotomized by the median: high vs. low) for mortality were investigated by Log-Rank tests based on Kaplan-Meier survival curves in patients stratified according to these variables. Results are presented with χ² and p-values.

Descriptive data are presented as medians with inter quartile ranges (IQR) or as n (proportions). P-values <0.05 were considered significant.

**Results**

**Patients**

The 163 patients had a median age of 62 years, were predominantly men (88%) and had an overall 7-, 30- and 180-day mortality rate of 20%, 33% and 35%, respectively. A comparable number of patients received the 33 and 36°C temperature intervention (n = 81 vs. n = 82, respectively). A detailed description of patient demography, medical history, admission physiology, outcome and characteristics of the cardiac arrest is provided in Table 1.

**Factors associated with p-catecholamines and biomarkers of endothelial activation and damage**

Levels of circulating catecholamines and endothelial derived biomarkers are displayed in Table 1.

**Demography and medical history.** P-catecholamines were neither associated with age nor gender (data not shown). Syndecan-1 correlated negatively with age (rho = -0.16,
Table 1. Demography, medical history, characteristics of the cardiac arrest, patient admission characteristics and outcome in all patients (n = 163) and in patients stratified according to admission serum thrombomodulin (high (> median) vs. low (≤ median), n = 160) admitted to a tertiary university hospital after out-of-hospital cardiac arrest (OHCA).

| Demography                  | All patients (n = 163) | High thrombomodulin (n = 78) | Low thrombomodulin (n = 82) | p-value |
|-----------------------------|------------------------|-------------------------------|----------------------------|---------|
| Age years                   | 62 (53–68)            | 64 (58–69)                    | 60 (51–66.75)               | 0.018   |
| Male gender n (%)           | 143 (88%)             | 76 (97%)                      | 64 (78%)                    | <0.001  |
| Body Mass Index kg/m²       | 25.4 (23.5–27.8)      | 25.0 (23.5–27.8)              | 25.4 (23.6–29.3)            | NS      |

| Medical history             |                        |                              |                            |         |
|-----------------------------|------------------------|-------------------------------|----------------------------|---------|
| Chronic heart failure n (%) | 6 (3.7%)               | 2 (2.6%)                      | 3 (3.7%)                    | NS      |
| Previous AMI n (%)          | 24 (14.7%)             | 11 (14.1%)                    | 11 (13.4%)                  | NS      |
| Ischemic heart disease n (%)| 33 (20.4%)             | 16 (20.8%)                    | 15 (18.3%)                  | NS      |
| Previous cardiac arrhythmia n (%) | 20 (12.3%) | 12 (15.4%)                    | 7 (8.5%)                    | NS      |
| Arterial hypertension n (%) | 50 (30.7%)             | 22 (28.2%)                    | 25 (30.5%)                  | NS      |
| Previous TIA or stroke n (%)| 10 (6.1%)              | 4 (5.1%)                      | 5 (6.1%)                    | NS      |
| Diabetes mellitus n (%)     | 22 (13.5%)             | 12 (15.4%)                    | 10 (12.2%)                  | NS      |
| Asthma or COPD n (%)        | 4 (2.5%)               | 2 (2.6%)                      | 2 (2.4%)                    | NS      |
| Previous PCI n (%)          | 12 (7.4%)              | 5 (6.4%)                      | 5 (6.1%)                    | NS      |
| Previous CABG n (%)         | 7 (4.3%)               | 3 (3.8%)                      | 3 (3.7%)                    | NS      |
| Pacemaker n (%)             | 3 (1.8%)               | 1 (1.3%)                      | 1 (1.2%)                    | NS      |

| Characteristics of the cardiac arrest | | | | |
|---------------------------------------|----------------|----------------|----------------|---------|
| Location (R / P / O) %                | 56%/43%/1%     | 56%/44%/0%     | 56%/42%/2%     | NS      |
| Bystander witnessed arrest n (%)      | 146 (89.6%)    | 69 (88.5%)     | 74 (90.2%)     | NS      |
| Bystander CPR n (%)                   | 129 (79.1%)    | 62 (79.5%)     | 64 (78%)       | NS      |
| Shockable rhythm n (%)                | 145 (89.0%)    | 68 (87.2%)     | 75 (91.5%)     | NS      |
| Adrenaline administration n (%)       | 122 (74.8%)    | 63 (80.8%)     | 56 (68.3%)     | 0.071   |
| Dose of adrenaline mg                 | 2 (1–4)        | 2 (1–4)        | 1 (0–3)        | 0.017   |
| Pre-hospital intubation n (%)          | 128 (79.0%)    | 57 (74.0%)     | 68 (82.9%)     | NS      |
| OHCA to ROSC min                      | 23 (14–30)     | 24 (14–30)     | 20 (14–32)     | NS      |

| Patient characteristics on admission | | | | |
|--------------------------------------|----------------|----------------|----------------|---------|
| Corneal reflex n (%)                 | 157 (96.3%)    | 75 (96.2%)     | 79 (96.3%)     | NS      |
| Pupil reflex n (%)                   | 150 (92.0%)    | 70 (89.7%)     | 77 (93.9%)     | NS      |
| pH -Log[H⁺]                          | 7.2 (7.1–7.3)  | 7.1 (7.0–7.2)  | 7.2 (7.1–7.3)  | 0.001   |
| Lactate ng/ml                        | 7.0 (3.8–11.0) | 8.4 (4.4–12.5) | 5.0 (3.0–9.3)  | 0.010   |
| Shock on admission n (%)             | 17 (10.4%)     | 11 (14.1%)     | 6 (7.3%)       | NS      |
| Initial temperature °C               | 35.5 (35.0–36.0)| 35.6 (34.7–36.0)| 35.5 (35.2–36.0)| NS      |
| ECG findings (U / S / L / A / O) %   | 25%/58%/7%/1%/9%| 27%/59%/4%/0%/10%| 23%/59%/10%/0%/8%| NS      |

| Biomarker levels on admission        | | | | |
|--------------------------------------|----------------|----------------|----------------|---------|
| OHCA to randomization min            | 135 (103–169) | 142 (104–169) | 130 (102–169) | NS      |
| Adrenaline pg/ml                     | 542 (108–1,128)| 792 (215–1,865)| 368 (95–1,025)| 0.041   |
| Noradrenaline pg/ml                  | 698 (389–1,542)| 1,090 (439–2,117)| 519 (308–1,206)| 0.004   |
| Syntecan-1 ng/ml                     | 152 (74–235)  | 161 (86–248)   | 147 (71–224)  | NS      |
| Thrombomodulin ng/ml                 | 7.0 (5.3–9.2) | 9.3 (7.7–11.6)| 5.4 (4.7–6.2) | NA      |
| sE-selectin ng/ml                    | 34 (27–45)    | 37 (28–45)     | 33 (25–44)    | NS      |
| sVE-cadherin ng/ml                   | 2,595 (2,303–3,174) | 2,818 (2,359–3,286) | 2,516 (2,185–3,019) | 0.016   |

| Outcome                              | | | | |
|--------------------------------------|----------------|----------------|----------------|---------|
| Discharge facility (O / R / H) %     | 66%/4%/30%     | 76%/2%/22%     | 60%/5%/35%     | NS      |
| 180-day CPC 1–2 n (%)                | 101 (62%)      | 40 (51%)       | 59 (72%)       | 0.007   |
| 180-day mRS 0–3 n (%)                | 102 (63%)      | 41 (53%)       | 59 (72%)       | 0.001   |

(Continued)
p = 0.048) whereas thrombomodulin correlated positively with age (rho = 0.22, p = 0.006) and was higher in men (7.3 vs. 5.2 ng/ml, p < 0.001). sE-selectin correlated with BMI (rho = 0.23, p = 0.003) and was higher in patients with diabetes (41 vs. 33 ng/ml, p = 0.028).

**Inter-correlations p-catecholamine and endothelial biomarker levels.** Admission levels of both p-adrenaline and p-noradrenaline were positively inter correlated (rho = 0.27, p = 0.001) and correlated with syndecan-1 (Fig. 1A and rho = 0.19, p = 0.022) and thrombomodulin (Fig. 1D and rho = 0.24, p = 0.003).

Among the endothelial biomarkers, sVE-cadherin correlated with thrombomodulin (rho = 0.23, p = 0.003) and sE-selectin (rho = 0.20, p = 0.014).

**Characteristics of the OHCA and admission variables.** Syndecan-1 correlated with the administered adrenaline dose, pH (Fig. 1BC), lactate (rho = 0.35, p < 0.001), time from OHCA to ROSC (rho = 0.31, p < 0.001) and number of defibrillations (rho = 0.25, p = 0.002) and thrombomodulin correlated with administered adrenaline dose, pH (Fig. 1EF) and lactate (rho = 0.25, p = 0.004).

Patients with STEMI-induced OHCA (n = 95, 58%) had almost 3-fold higher syndecan-1 levels compared to patients with other causes of OHCA (median 206 ng/ml (IQR 125–249) vs. 81 ng/ml (IQR 39–167), p < 0.001). STEMI OHCA patients received a prehospital bolus administration of unfractionated heparin (10,000 IE) and a higher proportion of STEMI OHCA patients received adrenaline during resuscitation (n = 77 (81%) vs. n = 45 (66%), p = 0.031).

Despite the higher adrenaline administration in STEMI OHCA patients, p-catecholamine levels were comparable in STEMI OHCA and other OHCA patients as well as sE-selectin and thrombomodulin levels (data not shown). sVE-cadherin was approximately 10% lower in STEMI OHCA patients (median 2,558 ng/ml (IQR 2,157–3,030) vs. 2,763 ng/ml (IQR 2405–3,294), p = 0.024). Survival was comparable in STEMI and other OHCA patients (data not shown).

The level of circulating catecholamines and endothelial biomarkers was comparable in patients stratified according to shockable (n = 145) vs. non-shockable rhythm (n = 18) (data not shown).
Factors independently associated with endothelial activation and damage

Multivariate linear regression analysis revealed that STEMI as cause of the OHCA, increased time from OHCA to ROSC and lower pH were independently associated with higher syndecan-1 (glycocalyx damage), explaining 36% of its variation (Table 2). Likewise, lower age, higher BMI and higher sVE-cadherin were independently associated with higher sE-selectin (endothelial activation); higher age, lower pH and higher sVE-cadherin were independently associated with higher thrombomodulin (endothelial cell injury) and higher thrombomodulin and higher sE-selectin were independently associated with higher sVE-cadherin (endothelial junction disruption) (Table 2).

Sympathoadrenal activation, endothelial damage and outcome

Log-Rank tests based on Kaplan-Meier survival curves for medians (high vs. low) of admission biomarker levels revealed that high p-adrenaline and high thrombomodulin were associated with increased 30-day (p = 0.006 and p = 0.004, respectively) and 180-day mortality (Fig. 2AB). High p-adrenaline was the only investigated biomarker associated with higher 7-day mortality (p = 0.005).

By Cox proportional-hazards analyses, high p-adrenaline (above median) was a univariate predictor of increased mortality (180-day: HR 2.0 (95%CI 1.7–3.5), χ² = 6.3, p = 0.012; 30-day: HR 2.2 (95%CI 1.2–3.8), χ² = 7.0, p = 0.008; 7-day: HR 2.8 (95%CI 1.3–6.1), χ² = 6.9, p = 0.008). Furthermore, thrombomodulin, sE-selectin, age, rhythm and time from OHCA to ROSC were univariate predictors of mortality (Table 3). In the adjusted models, higher thrombomodulin...
Table 2. Variables independently associated with admission biomarkers reflecting endothelial glycocalyx and cell activation and/or damage, and endothelial cell junction function (syndecan-1, sE-selectin, thrombomodulin and sVE-cadherin, respectively) by backwards multivariate linear regression analysis in 163 patients admitted to a tertiary university hospital after out-of-hospital cardiac arrest.

|                      | Adj. $R^2 = 0.36$ |                      | Adj. $R^2 = 0.14$ |                      | Adj. $R^2 = 0.24$ |                      | Adj. $R^2 = 0.13$ |
|----------------------|-------------------|----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                      | $\beta$ (95%CI)   | p                    | $\beta$ (95%CI)   | p                    | $\beta$ (95%CI)   | p                    | $\beta$ (95%CI)   | p                    |
| Age                  | NS                | -0.23 (-0.45--0.02) | 0.034             | 0.09 (0.04--0.14) | 0.001             | NS                |
| BMI                  | NS                | 0.94 (0.31--1.57)   | 0.004             | NS                |
| OHCA to ROSC         | 1.31 (0.48--2.13) | 0.002               | NS                |
| pH                   | -119 (-216--21)   | 0.018               | NS                | NS                | NS                | NS                |
| STEMI                | Yes               | 84 (56--111)        | <0.001            | NS                | NS                | NS                |
| Syndecan-1           | 2-fold            | NA                  | NA                | NS                | NS                | NS                |
| sE-selectin          | 2-fold            | NS                  | NA                | NA                | 251 (21--481)     | 0.033             |
| Thrombomodulin       | 2-fold            | NS                  | NS                | NA                | 333 (146--519)    | <0.001            |
| sVE-cadherin         | 2-fold            | NS                  | NA                | NA                | NA                | NA                |

Regression coefficients ($\beta$) with 95% confidence intervals (95%CI), p-values and adjusted $R^2$ are displayed, with p-values <0.05 shown in bold. Predicted changes in syndecan-1 (ng/ml, reflecting glycocalyx damage), sE-selectin (ng/ml, reflecting endothelial activation), Thrombomodulin (ng/ml, reflecting endothelial cell injury) and sVE-cadherin (ng/ml, reflecting endothelial junction disruption) associated with one unit increase in the explanatory variables (age (1 year older), BMI, number of defibrillations (NS all over, data not shown), time from OHCA to ROSC (min), pH, STEMI (yes), p-adrenaline and p-noradrenaline (10-fold higher, NS all over, data not shown), syndecan-1, thrombomodulin, sE-selectin and VE-cadherin (all 2-fold higher). NS, non-significant. NA, non-applicable.

doi:10.1371/journal.pone.0120914.t002

Fig 2. Kaplan-Meier plots displaying 180-day mortality in 163 OHCA patients stratified according to median levels (high vs. low) of A) plasma (p)-adrenaline and B) Serum thrombomodulin at hospital admission. Chi-square and p-values for log-rank tests are shown.

doi:10.1371/journal.pone.0120914.g002
Table 3. Cox Proportional Hazards models predicting 7-day, 30-day and 180-day mortality in 163 patients admitted to a tertiary university hospital after out-of-hospital cardiac arrest.

|                  | Univariate          | Syndecan-1          | sE-selectin         | Thrombomodulin        | sVE-cadherin          |
|------------------|---------------------|---------------------|---------------------|-----------------------|-----------------------|
|                  | (2-fold higher)     | (2-fold higher)     | (2-fold higher)     | (2-fold higher)       | (2-fold higher)       |
|                  | HR (95%CI) p        | HR (95%CI) p        | HR (95%CI) p        | HR (95%CI) p          | HR (95%CI) p          |
| 7-day mortality  |                     |                     |                     |                       |                       |
| univariate       | -                   | -                   | 1.29 (0.93–1.81) 0.126 | 0.51 (0.28–0.94) 0.031 | 2.09 (1.20–3.66) 0.010 |
| multivariate     | -                   | -                   | 1.13 (0.79–1.62) NS | 0.58 (0.31–1.10) 0.094 | 1.34 (0.74–2.44) NS |
| Gender           | male                | 1.01 (0.35–2.87) NS | 1.29 (0.40–4.12) NS | 1.23 (0.39–3.83) NS | 1.08 (0.32–3.64) NS |
| Age              | 1 year older        | 1.05 (1.02–1.08) <0.003 | 1.07 (1.03–1.11) <0.001 | 1.07 (1.02–1.10) 0.002 | 1.06 (1.02–1.10) 0.022 |
|                  |                     |                     |                     |                       |                       |
| Shockable rhythm | yes                 | 0.22 (0.10–0.46) <0.001 | 0.21 (0.10–0.45) <0.001 | 0.19 (0.08–0.41) <0.001 | 0.22 (0.10–0.49) <0.001 |
|                  |                     |                     |                     |                       |                       |
| OHCA to ROSC     | 1 min longer        | 1.02 (1.01–1.03) 0.002 | 1.01 (1.00–1.03) 0.065 | 1.02 (1.01–1.04) 0.009 | 1.02 (1.00–1.03) 0.028 |
|                  |                     |                     |                     |                       |                       |
| Shock at admission| yes                | 2.32 (0.96–5.61) 0.063 | 1.36 (0.49–3.81) NS | 0.92 (0.30–2.83) NS | 1.25 (0.44–3.56) NS |
|                  |                     |                     |                     |                       |                       |
| STEMI            | yes                 | 1.72 (0.82–3.62) 0.151 | 2.22 (0.97–5.09) 0.060 | 2.35 (1.01–5.46) 0.047 | 2.44 (1.09–5.47) 0.031 |
|                  |                     |                     |                     |                       |                       |
| 30-day mortality | univariate          | -                   | -                   | 1.00 (0.98–1.01) 0.72 | 0.69 (0.42–1.12) 0.135 |
|                  |                     |                     |                     |                       |                       |
|                  | multivariate        | -                   | -                   | 1.15 (0.87–1.53) NS | 0.68 (0.42–1.12) 0.129 |
|                  |                     |                     |                     |                       |                       |
| Gender           | male                | 0.91 (0.41–2.02) NS | 1.11 (0.45–2.73) NS | 1.08 (0.45–2.61) NS | 0.80 (0.31–2.05) NS |
| Age              | 1 year older        | 1.05 (1.02–1.07) <0.001 | 1.07 (1.04–1.10) <0.001 | 1.06 (1.03–1.09) <0.001 | 1.05 (1.02–1.09) <0.001 |
|                  |                     |                     |                     |                       |                       |
| Shockable rhythm | yes                 | 0.25 (0.13–0.46) <0.001 | 0.25 (0.13–0.49) <0.001 | 0.21 (0.10–0.42) <0.001 | 0.28 (0.14–0.57) <0.001 |
|                  |                     |                     |                     |                       |                       |
| OHCA to ROSC     | 1 min longer        | 1.02 (1.01–1.03) <0.001 | 1.02 (1.01–1.03) 0.007 | 1.02 (1.01–1.04) <0.001 | 1.02 (1.01–1.03) 0.002 |
|                  |                     |                     |                     |                       |                       |
| Shock at admission| yes                | 1.87 (0.88–3.97) 0.102 | 0.97 (0.38–2.44) NS | 0.73 (0.27–1.97) NS | 0.85 (0.33–2.18) NS |
|                  |                     |                     |                     |                       |                       |
| STEMI            | yes                 | 1.27 (0.73–2.21) NS | 1.72 (0.90–3.28) 0.099 | 1.88 (1.00–3.55) 0.051 | 1.91 (1.02–3.55) 0.042 |
|                  |                     |                     |                     |                       |                       |
| 180-day mortality| univariate          | -                   | -                   | 1.26 (0.98–1.62) 0.068 | 0.78 (0.48–1.24) 0.240 |
|                  |                     |                     |                     |                       |                       |
|                  | multivariate        | -                   | -                   | 1.16 (0.89–1.53) NS | 0.74 (0.46–1.18) NS |
|                  |                     |                     |                     |                       |                       |
| Gender           | male                | 0.99 (0.49–2.18) NS | 1.21 (0.49–2.99) NS | 1.18 (0.49–2.87) NS | 0.90 (0.35–2.30) NS |
| Age              | 1 year older        | 1.05 (1.02–1.07) <0.001 | 1.06 (1.04–1.09) <0.001 | 1.06 (1.03–1.09) <0.001 | 1.05 (1.02–1.08) <0.001 |
|                  |                     |                     |                     |                       |                       |
| Shockable rhythm | yes                 | 0.24 (0.13–0.43) <0.001 | 0.24 (0.13–0.47) <0.001 | 0.21 (0.11–0.40) <0.001 | 0.28 (0.14–0.54) <0.001 |
|                  |                     |                     |                     |                       |                       |
| OHCA to ROSC     | 1 min longer        | 1.02 (1.01–1.03) <0.001 | 1.02 (1.01–1.03) 0.005 | 1.02 (1.01–1.04) <0.001 | 1.02 (1.01–1.03) 0.001 |
|                  |                     |                     |                     |                       |                       |
| Shock at admission| yes                | 1.73 (0.82–3.64) 0.153 | 0.88 (0.35–2.20) NS | 0.67 (0.25–1.81) NS | 0.78 (0.31–1.99) NS |
|                  |                     |                     |                     |                       |                       |
| STEMI            | yes                 | 1.14 (0.67–1.93) NS | 1.44 (0.78–2.62) NS | 1.62 (0.89–2.94) 0.117 | 1.61 (0.90–2.90) 0.112 |

Hazard ratios (HR) with 95% confidence intervals (HR (95% CI)) and p-values associated with one unit increases in age (1 year older), gender (being male), shockable rhythm (yes), time from OHCA to ROSC (1 minute longer), shock at admission (yes) and 2-fold increases (log2 transformed) in serum levels of syndecan-1, sE-selectin, thrombomodulin and sVE-cadherin. Only p-values <0.20 are shown, with p<0.05 shown in bold.

doi:10.1371/journal.pone.0120914.003

remained an independent predictor of higher 30-day and 180-day mortality together with higher age, non-shockable rhythm and increased time from OHCA to ROSC (Table 3).

Patients with high vs. low degree of endothelial cell injury

Since thrombomodulin i.e., endothelial cell injury, was an independent predictor of mortality, we compared patients with high vs. low thrombomodulin levels at admission (Table 1) revealing that patients with high thrombomodulin were older, predominantly men, received a higher
adrenaline dose during resuscitation, had lower pH and higher lactate and had higher p-adrenaline and p-noradrenaline (both approximately 2-fold increased) and also higher sVE-cadherin (Table 1). Patients with high thrombomodulin levels also had a poorer outcome according to the Cerebral Performance Category (CPC) and modified Rankin scale (mRS) and they had higher mortality (Table 1).

**Discussion**

In the present study, OHCA patients presented with high and inter-correlated levels of circulating catecholamines and biomarkers of excessive endothelial damage. Increased time from OHCA to ROSC, lower pH and STEMI were independently associated with higher syndecan-1 levels, a marker of glycocalyx damage, whereas lower pH, higher age and higher sVE-cadherin were independently associated with higher thrombomodulin levels, a marker of endothelial cell injury. By Cox proportional-hazards analyses, high thrombomodulin levels independently predicted 30-day and 180-day mortality.

Acute critical illness is accompanied by excessive sympathoadrenal activation that induces widespread, dose-dependent effects on the vascular system [10, 11, 14], including the endothelium [15]. We have proposed [11] that endogenously released catecholamines ensure oxygen supply to vital organs in acute critical illness by balancing the clotting ability of the circulating blood according to the degree of endothelial anti-/procoagulation in the microcirculation. Hereby, progressive endothelial damage (and procoagulation) in the microcirculation is balanced by increasing hypocoagulability (coagulopathy) in the circulating blood [11]. Given this, the evolutionary rational for the coagulopathy observed in many acute critically ill patients [28–30], may be that evolution has prioritized tissue oxygenation above hemostasis. We have reported of associations between- and negative predictive values of high circulating catecholamines and endothelial damage in trauma, sepsis and STEMI patients [18–21]. In line with this, the present study found that circulating levels of adrenaline and noradrenaline correlated positively with syndecan-1 and thrombomodulin levels, biomarkers of endothelial glycocalyx and cell damage, respectively [23, 24, 26]. Furthermore, high circulating thrombomodulin was an independent predictor of mortality. The present study thus supports the notion that different “injurious” hits can mount a similar, universal response, characterized by excessive sympathoadrenal activation, endothelial damage and coagulopathy.

Gando et al [7] suggested years ago that the endothelial damage observed in OHCA patients could in part be attributed to both exogenous administered and endogenously released catecholamines. Recently, Hagihara et al [16] reported in a prospective observational propensity score analysis of data from 417,188 OHCA patients that use of prehospital adrenaline was associated with increased chance of ROSC before hospital arrival but also with decreased chance of survival and good functional outcomes 1 month after the event. This is in accordance with previous studies also questioning the beneficial effect of adrenaline administration in CA [17, 31]. Interestingly, several retrospective studies of trauma-, sepsis- and surgical patients have reported a paradoxical survival benefits for patients receiving β-blockers as part of their regular medication at the time of the injurious hit [32–36], despite these patients often being older and suffering from more co-morbidities compared to patients not receiving β-blockers. Randomized clinical studies comparing β-blockers with placebo in trauma, sepsis and patients suffering from acute ischemic heart disease have confirmed these findings [37, 38]. It is tempting to speculate that the beneficial effects of β-blockers observed in many acute critically ill patients may in part be due to protective effects on the endothelium in conditions with excessive catecholamine release.
Glycocalyx damage is associated with pathophysiologic sequels like capillary leakage, accelerated inflammation, platelet activation and loss of vascular responsiveness [39, 40]. Previous studies investigating circulating syndecan-1 levels as a surrogate for endothelial glycocalyx damage have reported increased levels in trauma [18, 41], sepsis [20, 42], major vascular- [23] and abdominal surgery [42], STEMI [21] and OHCA [8] patients, with the highest levels in non-survivors and/or the most sick patients. In the present study, STEMI OHCA patients had several-fold higher syndecan-1 levels compared to patients with other causes of OHCA. It is not known if this is due to downstream effects of the STEMI, to iatrogenous factors such as the heparin IV injection given to these patients or to other factors. It is well described that heparin can destabilize the endothelial glycocalyx [43] through induction of a rapid dose-dependent release of glycocalyx adsorbed heparan sulphate-bound proteins [44, 45], and it is possible that this may contribute to accelerated glycocalyx damage following a “second hit” (e.g. ischemia/reperfusion) [23]. However, shocked STEMI patients without cardiac arrest who receive a comparable IV injection of heparin [21] display lower circulating syndecan-1 level compared to STEMI OHCA patients (median 129 ng/ml vs. 206 ng/ml), indicating that other factors than heparin i.e., exogenous adrenaline administration, defibrillations, time from OHCA to ROSC, pH and lactate (shock) (these were all correlated with syndecan-1 in the present study) contribute to the glycocalyx damage [8, 39].

There is emerging evidence that the change from a normal quiescent endothelium to endothelial cell activation, glycocalyx damage, junctional disruption and ultimate endothelial cell injury reflects a progression from reversible to irreversible endothelial damage [25, 41, 46]. In the present study, we investigated different endothelial derived molecules as surrogate markers for glycocalyx damage, endothelial cell activation, endothelial junction disruption and endothelial cell injury, to reveal the influence of progressive endothelial disruption on outcome in OHCA patients. Interestingly, we found that biomarkers reflecting endothelial damage (syndecan-1, thrombomodulin) were independently associated with shock degree (time from OHCA to ROSC, pH) whereas biomarkers reflecting endothelial activation (sE-selectin) and junctional disruption (sVE-cadherin) were independently associated with patient demography and/or other endothelial biomarkers. The finding that sE-selectin, sVE-cadherin and thrombomodulin were inter correlated supports the notion that endothelial activation, junctional disruption and cell injury are linked at the biologic level. Finally, we found that high circulating thrombomodulin was an independent predictor of increased mortality. In accordance with previous studies, higher age, male gender, high catecholamine levels and shock were all associated with high thrombomodulin levels [21]. The strong predictive value of thrombomodulin supports the notion that patients with the most severe form of endothelial injury have the poorest outcome. The finding that post-CA therapeutic hypothermia may attenuate the anoxic brain injury and improve outcome [47, 48], emphasizes that therapeutic interventions applied after ROSC can be beneficial. Given this, we infer that interventions aiming at protecting and/or restoring the endothelium, administered at the earliest possible, may be able to alleviate the downstream endothelial damage and the ensuing PCAS, and thereby improve patient outcome. A randomized clinical trial to test this hypothesis is currently underway.

The present study had several limitations. First, the observational nature of study does not allow independent evaluations of the cause-and-effect relationships suggested. Second, the IV heparin injection to STEMI OHCA patients makes it impossible to differentiate between potential effects of the STEMI itself vs. heparin on glycocalyx damage. Third, the study was a post hoc sub-study of the TTM trial, a randomized multicenter trial, where we only investigated patients included at a single site [49]. Given this, the present findings should be considered hypothesis-generating and the p-values as explorative in nature.
Conclusions
In the present study, OHCA patients presented with evidence of excessive endothelial damage that correlated with circulating catecholamine levels, time from OHCA to ROSC and biochemical shock markers. High thrombomodulin levels, reflecting endothelial cell injury, independently predicted increased mortality. We speculate that interventions aiming at protecting and/or restoring the endothelium may be of value in OHCA patients.

Acknowledgments
Karen Dyeremose and Helena Marie Stjernkvist are thanked for the skilled technical assistance.

Author Contributions
Conceived and designed the experiments: PIJ JBJ JK MW CH SRO. Performed the experiments: PIJ JBJ JK MW CH SRO. Analyzed the data: PIJ JK CH SRO. Contributed reagents/materials/analysis tools: PIJ JBJ JK MW CH SRO. Wrote the paper: PIJ JBJ JK MW CH SRO.

References
1. Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Auferheide TP, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA. 2008; 300: 1423–1431. doi:10.1001/jama.300.12.1423 PMID: 18812533
2. Reynolds JC, Frisch A, Rittenberger JC, Callaway CW. Duration of resuscitation efforts and functional outcome after out-of-hospital cardiac arrest: when should we change to novel therapies? Circulation. 2013; 128: 2488–2494. doi: 10.1161/CIRCULATIONAHA.113.002408 PMID: 24243885
3. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Bottiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation. 2008; 118: 2452–2483. doi:10.1161/CIRCULATIONAHA.108.190652 PMID: 18948368
4. Stub D, Bernard S, Duffy SJ, Kaye DM. Post cardiac arrest syndrome: a review of therapeutic strategies. Circulation. 2011; 123: 1428–1435. doi:10.1161/CIRCULATIONAHA.110.988725 PMID: 21464058
5. Adrie C, dib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation. 2002; 106: 562–568. PMID: 12147537
6. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010; 38: S35–S42. doi: 10.1097/CCM.0b013e3181c9e31d PMID: 2083912
7. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Out-of-hospital cardiac arrest increases soluble vascular endothelial adhesion molecules and neutrophil elastase associated with endothelial injury. Intensive Care Med. 2000; 26: 38–44. PMID: 10663278
8. Grundmann S, Fink K, Rabadzhieva L, Bourgeois N, Schwab T, Moser M, et al. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. Resuscitation. 2012; 83: 715–720. doi: 10.1016/j.resuscitation.2012.01.028 PMID: 22306259
9. Wada T, Jesmin S, Gando S, Yanagida Y, Mizugaki A, Sultana SN, et al. Angiogenic factors and their soluble receptors predict organ dysfunction and mortality in post-cardiac arrest syndrome. Crit Care. 2012; 16: R171. doi: 10.1186/cc11648 PMID: 23021336
10. Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009; 24: 293–316. doi: 10.1177/0885066609340519 PMID: 19703817
11. Johansson PI, Ostrowski SR. Acute coagulopathy of trauma: Balancing progressive catecholamine induced endothelial activation and damage by fluid phase anticoagulation. Med Hypotheses. 2010; 75: 564–567. doi: 10.1016/j.mehy.2010.07.031 PMID: 20708846
12. Makhmudov RM, Mamedov Y, Dolgov VV, Repin VS. Catecholamine-mediated injury to endothelium in rabbit perfused aorta: a quantitative analysis by scanning electron microscopy. Cor Vasa. 1985; 27: 456–463. PMID: 4092474
13. Kristova V, Kriska M, Canova R, Hejdova E, Kobzova D, Dobrocky P. Endothelial changes following repeated effect of vasoconstrictive substances in vitro. Acta Physiol Hung. 1993; 81: 363–370. PMID: 8067251
14. Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med. 1980; 303: 436–444. PMID: 6248784
15. von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol. 2000; 65: 357–369. PMID: 11168493
16. Hagihara A, Hasegawa M, Abe T, Nagata T, Wakata Y, Miyazaki S. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012; 307: 1161–1168. doi: 10.1001/jama.2012.294 PMID: 22436956
17. Callaway CW. Questioning the use of epinephrine to treat cardiac arrest. JAMA. 2012; 307: 1198–1200. doi: 10.1001/jama.2012.313 PMID: 22436961
18. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A High Admission Syndecan-1 Level, A Marker of Endothelial Glycocalyx Degradation, is Associated With Inflammation, Protein C Depletion, Fibrinolysis, and Increased Mortality in Trauma Patients. Ann Surg. 2011; 254: 194–200. doi: 10.1097/SLA.0b013e318226113d PMID: 21772125
19. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg. 2012; 72: 428–436. PMID: 22439205
20. Ostrowski SR, Berg RMG, Windeløv NA. Ploving RR, Møller K, Johansson PI. Coagulopathy, catecholamines and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis. A prospective study. J Crit Care. 2013; 28: 586–596. doi: 10.1016/j.jcrc.2013.04.010 PMID: 23731819
21. Ostrowski SR, Pedersen SH, Jensen JS, Mogelvang R, Johansson PI. Acute myocardial infarction is associated with endothelial glycocalyx and cell damage and a parallel increase in circulating catecholamines. Crit Care. 2013; 17: R32. doi: 10.1186/cc12532 PMID: 23433557
22. Nielsen N, Wetterlev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013; 369: 2197–2206. doi: 10.1056/NEJMoa130519 PMID: 24237006
23. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007; 116: 1896–1906. PMID: 17923576
24. Blann A, Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol Microcirc. 1997; 17: 3–11. PMID: 9181753
25. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis. 2000; 11: 623–630. PMID: 11085282
26. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost. 1991; 65: 618–623. PMID: 1651569
27. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2008; 28: 223–232. PMID: 18162609
28. Holcomb JB. A Novel and Potentially Unifying Mechanism for Shock Induced Early Coagulopathy. Ann Surg. 2011; 254: 201–202. doi: 10.1097/SLA.0b013e318226483d PMID: 21694580
29. Gando S, Sawamura A, Hayakawa M. Trauma, Shock, and Disseminated Intravascular Coagulation: Lessons from the Classical Literature. Ann Surg. 2011; 254: 10–19. doi: 10.1097/SLA.0b013e31821221b1 PMID: 21368657
30. Hess JR, Lawson JH. The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma. 2006; 60: S12–S19. PMID: 16763475
31. Olasveengen TM, Sunde K, Brunborg C, Thowsen J, Steen PA, Wik L. Intravenous drug administration during out-of-hospital cardiac arrest: a randomized trial. JAMA. 2009; 302: 2222–2229. doi: 10.1001/jama.2009.1729 PMID: 19934423
32. Bukur M, Lustenberger T, Cotton B, Arbabi S, Talving P, Salim A, et al. Beta-blocker exposure in the absence of significant head injuries is associated with reduced mortality in critically ill patients. Am J Surg. 2012; 204: 697–703. doi: 10.1016/j.amjsurg.2012.02.007 PMID: 22578406
33. Schroeppel TJ, Fischer PE, Zarzaur BL, Magnotti LJ, Clement LP, Fabian TC, et al. Beta-adrenergic blockade and traumatic brain injury: protective? J Trauma. 2010; 69: 776–782. doi: 10.1097/TA.0b013e3181e981b8 PMID: 20938265
34. Macchia A, Romero M, Comignani PD, Mariani J, D’Ettorre A, Prini N, et al. Previous prescription of beta-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med. 2012; 40: 2768–2772. PMID: 2284934

35. Christensen S, Johansen MB, Tonnesen E, Larsson A, Pedersen L, Lemeshow S, et al. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit Care. 2011; 15: R87. doi: 10.1186/cc10085 PMID: 21385356

36. London MJ, Hur H, Schwartz GG, Henderson WG. Association of perioperative beta-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013; 309: 1704–1713. doi: 10.1001/jama.2013.4135 PMID: 23613075

37. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic Shock: A Randomized Clinical Trial. JAMA. 2013; 310: 1683–1691. doi: 10.1001/jama.2013.278477 PMID: 24108526

38. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: 529–555. doi: 10.1161/CIR.0b013e3182742c84 PMID: 23247303

39. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc Res. 2010; 87: 300–310. doi: 10.1093/cvr/cvq137 PMID: 20462866

40. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and altered microvascular permeability. J Pathol. 2012; 226: 562–574. doi: 10.1002/path.3964

41. Haywood-Watson RJ, Holcomb JB, Gonzalez EA, Peng Z, Pati S, Park PW, et al. Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation. PLoS ONE. 2011; 6: e23530. doi: 10.1371/journal.pone.0023530 PMID: 21886795

42. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, et al. Sepsis and Major Abdominal Surgery Lead to Flaking of the Endothelial Glycocalix. J Surg Res. 2011; 165: 136–141. doi: 10.1016/j.jss.2009.04.034 PMID: 19560161

43. VanTeeffelen JW, Brands J, Jansen C, Spaan JA, Vink H. Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension. 2007; 50: 261–267. PMID: 17452501

44. Becker RC. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2005; 150: 189–192. PMID: 16086916

45. Myrup B, Yokoyama H, Kristiansen OP, Ostergaard PB, Ollevcrona T. Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes. Diabet Med. 2004; 21: 1135–1140. PMID: 15384962

46. Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, et al. Plasma Restoration of Endothelial Glycocalyx in a Rodent Model of Hemorrhagic Shock. Anesth Analg. 2011; 112: 1289–1295. doi: 10.1213/ane.0b013e3182103855 PMID: 21346161

47. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002; 346: 549–556. PMID: 11856793

48. Bernard SA, Gray TW, Buist MD, Jones BM, Silverstein W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002; 346: 557–563. PMID: 11856794

49. Nielsen N, Wetterslev J, al-Subaie N, Andersson B, Bro-Jeppesen J, Bishop G, et al. Target Temperature Management after out-of-hospital cardiac arrest—a randomized, parallel-group, assessor-blinded clinical trial—rationale and design. Am Heart J. 2012; 163: 541–548. doi: 10.1016/j.ahj.2012.01.013 PMID: 22520518